Management of HIV/AIDS

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Retrieved on: 
Tuesday, March 5, 2024
AIDS, Health, Infectious Diseases, Hospitals, Research, Science, Biotechnology, Infection, BCG, Medicine, MD, FDA, Safety, Hook effect, NMIBC, Rockefeller University, University, ART, Patient, Journal, NK, Management of HIV/AIDS, HIV/AIDS, HIV, Viral load, Immune system, Vaccine

ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.

Key Points: 
  • ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.
  • All participants in this Phase 1 study experienced significant reduction in infection levels following treatment with N-803.
  • HIV can disable NK cells—a frontline defense against viral infections—making it difficult to clear the infection.
  • The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells.

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Retrieved on: 
Wednesday, February 22, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, AIDS, Health, Pharmaceutical, General Health, Science, MSD, PWH, Infection, Randomness, Management of HIV/AIDS, HIV, Conference on Retroviruses and Opportunistic Infections, HIV-1, NYSE, Fungal infection, Islatravir, Vargo, Subtypes of HIV, Bictegravir/emtricitabine/tenofovir alafenamide, Merck & Co., Conference, DOR, MRK, CROI, Pharmaceutical industry, Dietary supplement, Silviculture, Merck, R, Safety

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has opened enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.
  • Select Merck abstracts for islatravir at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023 include:
    Switch to DOR/ISL (100/0.75MG) QD From B/F/TAF: Week 48 Results From a Phase 3 Trial.
  • For more than 35 years, Merck has been committed to scientific research and discovery (R&D) in HIV.
  • We remain committed to working hand-in-hand with our partners in the global HIV community to address the complex challenges that impede progress toward ending the epidemic.

Lundquist Institute Investigator Dr. Eric Daar and Research Team Find That HIV Patients Benefit from Ingestible Sensor Technology on HIV Treatment

Retrieved on: 
Tuesday, November 15, 2022
UCLA School of Dentistry, Population health, LOS, Harvard University, Monitoring, Information technology, David Geffen School of Medicine at UCLA, Harbor–UCLA Medical Center, Mental health, Yale University, ARV, Patient, Edible, Media contacts database, HIV-AIDS, HIV Medicine, UCLA, Lundquist, Research, Management of HIV/AIDS, Record, Institute of Health and Biomedical Innovation, Division, Nebraska Medicine, HIV, National Institute of Mental Health, OIP Sensor Systems, HIV/AIDS, Pharmaceutical industry, Medical device, Dentistry, Medicine

The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.

Key Points: 
  • The findings Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Carecontrolled, Randomized Trial were published on November 11 in The Lancet Ebiomedicine.
  • The team of researchers included investigators from UCLA, Nebraska Medical Center, Yale University, and Harvard University.
  • When ingested, it is sensed by a patchwith an embedded monitor and sensor that isworn by the patient.
  • Our study delivered especially promising results for those who have significant challenges in adhering to antiretroviral medications.

ELITE WORLD GROUP FILES NEW SUIT IN DELAWARE, ALLEGING FORMER CEO JULIA HAART EMBEZZLED MILLIONS DURING TENURE

Retrieved on: 
Tuesday, June 14, 2022
Private law, EWG, Family, LLC, Complaint, Investment, American Express, NEW, Online gambling, Amusement park, Management of HIV/AIDS

NEW YORK, June 13, 2022 /PRNewswire/ -- Elite World Group, LLC (EWG), the world's first talent media company, just filed a complaint in Delaware claiming former CEO Julia Haart stole millions of corporate assets for her own personal indulgences, and then lied to try to cover it up.

Key Points: 
  • "A life of 'faking it' that is, lying and stealing may have worked for Haart before, but it cannot work for her in court.
  • NEW YORK, June 13, 2022 /PRNewswire/ -- Elite World Group, LLC (EWG), the world's first talent media company, just filed a complaint in Delaware claiming former CEO Julia Haart stole millions of corporate assets for her own personal indulgences, and then lied to try to cover it up.
  • Haart used her positions to access millions of dollars in EWG and E1972 assets, including:
    $1 million in a single year on clothes, accessories and makeup for herself.
  • Haart went so far as to claim purchases were investments in her "personal image" and brand.

SILVIO SCAGLIA DEFEATS JULIA HAART IN DELAWARE CASE

Retrieved on: 
Friday, May 27, 2022
EWG, II, NEW, Management of HIV/AIDS, Hon, IV, Ownership, Netflix, III, CEO, Cryptocurrency, Scaglia

NEW YORK , May 27, 2022 /PRNewswire/ -- Renowned tech entrepreneur and global talent agency chairman Silvio Scaglia received a major win in Delaware when a judge ruled Scaglia to be the controlling owner of Elite World Group ("EWG") and its parent company, Freedom Holding, Inc. This decision comes in response to a petition filed by Julia Haart, Scaglia's estranged wife, on February 11, 2022, claiming equal ownership of the company – just two days after being terminated as CEO of EWG.

Key Points: 
  • NEW YORK, May 27, 2022 /PRNewswire/ -- Renowned tech entrepreneur and global talent agency chairman Silvio Scaglia received a major win in Delaware when a judge ruled Scaglia to be the controlling owner of Elite World Group ("EWG") and its parent company, Freedom Holding, Inc.
  • "I always had faith that 'fake it till you make it,' would not hold up in a court of law," Scaglia said.
  • Even after Vice Chancellor Zurn's final order, Ms. Haart could not resist trying to 'fake it,' saying that the court's decision wasn't 'final.'"
  • "The apartment is in what is now proven company property which I believe Ms. Haart is no longer entitled to use," Davis said.

UPDATED: February 14, 2022 - Elite World Group Chairman Silvio Scaglia announces retaining attorney Lanny J. Davis as legal advisor to correct the record from false and misleading public accusations Julia Haart has made against him

Retrieved on: 
Tuesday, February 15, 2022
Trident, Mark (given name), Minesweeper, NY, Complaint, Supreme court, PR, Letter, Divorce, Management of HIV/AIDS, 2005 Forbes Global CEO Conference, New York Supreme Court, Ridesharing company

Mr. Scaglia recently filed for divorce from Ms. Haart.

Key Points: 
  • Mr. Scaglia recently filed for divorce from Ms. Haart.
  • On February 10, Mr. Scaglia and Freedom Holding filed a lawsuit in NY State Supreme Court in Manhattan alleging that Ms. Haart had been given notice of termination, citing her poor performance and excessive spending.
  • In the February 10 NY State Supreme Court lawsuit, the legal filing alleged that an unauthorized transfer byMs.
  • Davis noted that those two words together fairly be interpreted to mean "possible criminal conduct that might justify a criminal investigation and action against Ms.

Data Presented at the 11th IAS Conference on HIV Science Supports AREV’s Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation

Retrieved on: 
Thursday, July 22, 2021
Articles, HIV/AIDS, Retroviridae, Branches of biology, Limbic system, Malnutrition, Motivation, Neuropsychology, HIV, Management of HIV/AIDS, Nutritional challenges of HIV/AIDS

At the IAS Conference on HIV Science, University of Cincinnati and Florida International University researchers presented a study demonstrating that persistent immune activation was associated with chronic food insecurity and malnutrition.

Key Points: 
  • At the IAS Conference on HIV Science, University of Cincinnati and Florida International University researchers presented a study demonstrating that persistent immune activation was associated with chronic food insecurity and malnutrition.
  • Titled Food insecurity is associated with increased immune activation in people living with HIV, this study demonstrated compelling data establishing the biological link between malnutrition and chronic disease in HIV populations.
  • The research further showed immune activation remained consistent in relationship to food insecurity, which is characteristic of immune dysfunction in patients challenged by viral infections.
  • Without addressing the nutritional state of those suffering acute malnutrition, HIV therapy may be of no use to them.

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Retrieved on: 
Saturday, July 17, 2021
AIDS, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Medical specialties, Hepatotoxins, Prevention of HIV/AIDS, HIV/AIDS, Management of HIV/AIDS, Zidovudine, HIV, Lenacapavir, Discovery and development of HIV-protease inhibitors, HIV vaccine development

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

Key Points: 
  • If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
  • Lenacapavir is a potentially first-in-class capsid inhibitor without overlapping resistance with any currently approved antiretroviral therapy (ART).
  • Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
  • Data presented at AIDS 2020 from a Phase 1 study support further evaluation of lenacapavir administered subcutaneously every six months for both HIV-1 treatment and prevention.

CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

Retrieved on: 
Monday, July 12, 2021
Leronlimab, Drugs, Breast cancer, Triple-negative breast cancer, Health, Medical specialties, Management of HIV/AIDS, Cancer, CCR5 receptor antagonist

We believe these safety findings are a tremendous step forward for CytoDyns oncology program for all tumors that have the potential to be treated with leronlimab.

Key Points: 
  • We believe these safety findings are a tremendous step forward for CytoDyns oncology program for all tumors that have the potential to be treated with leronlimab.
  • Physicians and patients have shared their experiences with us supporting their belief that leronlimab has prolonged lives.
  • It is an honor to be entrusted with this mission and we will redouble our efforts to achieve the best outcome possible for leronlimab.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

Retrieved on: 
Thursday, June 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, AIDS, Health, Clinical trials, HIV/AIDS, Medical specialties, Antibodies, Neutralizing antibody, Management of HIV/AIDS, HIV, Signs and symptoms of HIV/AIDS, Broadly neutralizing HIV-1 antibodies, the ACTG, ImmunityBio, THE ACTG, IMMUNITYBIO

The second study, which was announced earlier this year and is in Phase 2, will evaluate Anktiva in combination with antiretroviral therapy during acute HIV infection.

Key Points: 
  • The second study, which was announced earlier this year and is in Phase 2, will evaluate Anktiva in combination with antiretroviral therapy during acute HIV infection.
  • The actions of bNAbs (or antibodies that neutralize a broad number of variants of HIV) are well-matched to that of Anktiva.
  • Ultimately, the study will test whether this approach results in immune control of HIV when ART is paused, with careful monitoring.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.